• Publications
  • Influence
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
BACKGROUND Olaparib is a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in homozygous BRCA-deficient cells. We aimed to assess the efficacy andExpand
  • 1,536
  • 32
  • PDF
Triple negative tumours: a critical review
Breast cancer is a heterogeneous disease that encompasses several distinct entities with remarkably different biological characteristics and clinical behaviour. Currently, breast cancer patients areExpand
  • 830
  • 30
BRCA1 dysfunction in sporadic basal-like breast cancer
Basal-like breast cancers form a distinct subtype of breast cancer characterized by the expression of markers expressed in normal basal/myoepithelial cells. Breast cancers arising in carriers ofExpand
  • 579
  • 29
The Life History of 21 Breast Cancers
Serena Nik-Zainal, Peter Van Loo, David C. Wedge, Ludmil B. Alexandrov, Christopher D. Greenman, King Wai Lau, Keiran Raine, David Jones, John Marshall, Manasa Ramakrishna, Adam Shlien, Susanna L.Expand
  • 192
  • 12
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer
IntroductionBreast cancer remains a significant scientific, clinical and societal challenge. This gap analysis has reviewed and critically assessed enduring issues and new challenges emerging fromExpand
  • 317
  • 10
  • PDF
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
Inhibitors of poly (ADP‐ribose)‐polymerase‐1 (PARP) are highly lethal to cells with deficiencies in BRCA1, BRCA2 or other components of the homologous recombination pathway. This has led to PARPExpand
  • 295
  • 10
  • PDF
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.
Therapies that target estrogen signaling have transformed the treatment of breast cancer. However, the effectiveness of these agents is limited by the development of resistance. Here, an RNAi screenExpand
  • 187
  • 7
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
Breast Cancer Program, Istituto Europeo di Oncologia, Milano, Italy; Breast Oncology Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA; Department of Surgery, ComprehensiveExpand
  • 228
  • 7
  • PDF
Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers.
The glycome acts as an essential interface between cells and the surrounding microenvironment. However, changes in glycosylation occur in nearly all breast cancers, which can alter this interaction.Expand
  • 141
  • 6
  • PDF
Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles
Basal-like invasive breast cancer is an important clinical group because of its association with a triple-negative phenotype defined by the lack of expression of estrogen, progesterone and humanExpand
  • 83
  • 5